DCP – Clinical Value of Diagnostics https://clinicalvalue.com Thu, 27 Mar 2025 06:20:10 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://i0.wp.com/clinicalvalue.com/wp-content/uploads/2023/01/apple-touch-icon.png?fit=32%2C32&ssl=1 DCP – Clinical Value of Diagnostics https://clinicalvalue.com 32 32 225041835 Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung Memorial Hospital https://clinicalvalue.com/pioneering-innovations-in-hcc-detection-for-enhance-patient-outcomes-chang-gung-memorial-hospital/ Mon, 19 Aug 2024 08:29:36 +0000 https://clinicalvalue.com/?p=8918 ...

The post Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung Memorial Hospital appeared first on Clinical Value of Diagnostics.

]]>

Dr. Ming-Ling Chang and Dr. Chung-Guei Huang talk about their experience using PIVKA-II, and their expectations for digital algorithms in HCC surveillance

Interview transcript:

MLC: Ming-Ling Chang

CGH: Chung-Guei Huang

Introduction

MLC: Hi, everyone, I am Dr. Ming-Ling Chang. Currently, I am the Director of the Department of Hepatology and the Gastroenterology of the Chang Gung Memorial Hospital at the Lin-Kou.

CGH: Hello everyone, I am Dr. Chung-Guei Huang. Currently, I am the Director of Department of Medical Laboratory at Lin-Kou Chang Gung Memorial Hospital.

MLC: Chang Gung Memorial Hospital is the biggest chain hospital in
Taiwan with 10 branches and more than 11,000 beds. Chang Gung Memorial Hospital at Lin-Kou is the headquarter among this healthcare system.

CGH: Our laboratory has been CAP accredited since 2003, which means every report from our laboratory meet international standards requirements; we’ve been maintaining CAP accreditation for over 20 years. Beyond CAP accreditation, we also got National Golden Quality Award several times in the past 10 years. Over 1 million tests were reported from our laboratory every month.

What are the challenges in HCC surveillance & diagnosis and testing capacity in your institution?

MLC: In Chang Gung Memorial Hospital, for patients with liver disease, we usually recommend patients with hepatitis to visit our outpatient departments every six months; while those with cirrhosis might have to come every three months. We also conduct liver cancer surveillance by using ultrasound and the alpha fetoprotein, which is AFP. However, not all patients with liver cancer can be diagnosed early despite these measures. The main reason is that the detection rate of tumor by ultrasound is affected by factors such as tumor size, the presence of fatty liver and the liver fibrosis. Moreover, the traditional serum tumor marker AFP only rises in the serum of less than half of the patients with early liver cancer, and can be affected by hepatitis flare leading to false positive results. So, patients with early-stage liver cancer can’t receive timely treatment, and this crucially affects their survival.

CGH: Because of the robust national health insurance system, there are lots of medical behaviors such as blood testing. And the increasing testing loads prompting laboratories to integrate and optimized workflows continuously. Our team had been putting many efforts on streamlining processes for over one decade, making our lab smarter and more efficient, including the application of Artificial Intelligence, business intelligence system, HIMSS 7 close loop system, which helps us successfully release additional testing capacity.

What are the important factors for your lab to consider when selecting a tumor marker?

CGH: As a certificated laboratory, a well-validated assay with official registration approval like CE or FDA is definitely our first priority.

Please share your experience implementing PIVKA-II.

MLC: Currently, in Taiwan, under the National Health Insurance, patients with liver cirrhosis and hepatocellular carcinoma, which is HCC, are entitled to undergo PIVKA-II testing twice a year. This can be complemented with ultrasound and AFP testing. Given the complementary roles of PIVKA-II and AFP in HCC surveillance, their combined use enhances the sensitivity of HCC surveillance, especially for the detection of early-stage HCC. Within hospitals, there have been numerous cases of liver cancer without elevations in AFP levels that were identified through PIVKA-II testing. These patients may exhibit either significant or insignificant ultrasound findings, providing clinicians with greater confidence to proceed with further computer tomography, which is CT, or magnetic resonance imaging, which is MRI, to confirm the diagnosis of liver cancer.

What are your expectations for digital algorithms for HCC surveillance and how is your experience with the new HCC digital algorithm so far?
CGMH is evaluating a new HCC digital algorithm in a clinical study.

MLC: To assess the severity of liver disease, we commonly rely on some algorithms or scores such as fibrosis-4, which is FIB-4, or Child-Pugh score for clinical or decision making. So, there is considerable anticipation for scores like GAAD, which integrates high-risk factors for liver cancer including G for gender, A for age, A for AFP, and the D for DCP, which is PIVKA-II. This integration is expected to serve as an early liver cancer surveillance tool, enhancing efficacy of surveillance, facilitating treatment improvement, and improving patient survival rates. We are still on the road to accumulate the research data on GAAD. If the performance meets expectations, surely, we would like to enroll all patients with high risk for HCC to undergo regular surveillance with GAAD.

CGH: The implementation and calculation framework of GAAD is a brand new trying for laboratories. However, with the rapid development of digitization, AI, and personalized medicine, laboratories are not only dealing with specimens and instruments but also digital algorithms. Facing the trends, laboratories have also strengthened efforts in digital medical talent and ensuring information security.

What advice would you give to other healthcare institutions or professionals looking to improve their HCC management?

MLC: To enhance screening efficacies for early liver cancer in Taiwan, which is a viral hepatitis endemic country, in addition to reinforcing public awareness of liver disease and encouraging regular surveillance among high-risk groups, the surveillance tools should be enhanced. It is important to follow health insurance coverage guidelines when incorporating PIVKA-II. Hopefully, in the future, digital algorithms like GAAD can be applied to further enhance early liver cancer detection rates.

CGH: The values of the testing data offers clinicians as evidence on clinical decisions. In recent years, we focused on the collaboration and communication with clinicians, which contributed to get a better understanding of their perspectives. This allowed us to integrate resources into what clinicians really need and enhancing the value of testing.

What is CGMH’s vision for liver disease and HCC management for the future?

MLC: Hopefully, through collaborative efforts across different units within the healthcare system, the caring for liver diseases, including hepatitis cirrhosis, and HCC, could be enhanced through effective screening, diagnosis, and treatment. In the future, the patients’ quality of life and the survival rates could be improved ultimately.

CGH: Delivering fast and accurate reports is a fundamental requirement for any laboratory. Additionally, we are actively introducing cutting-edge technologies to provide more valuable insights, thereby enhancing early diagnosis rates and patient survival rates.

The views and opinions expressed by Dr. Ming-Ling Chang and Dr. Chung-Guei Huang are their own views and opinions. Roche disclaims all liability in relation to these views and opinions.

The post Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung Memorial Hospital appeared first on Clinical Value of Diagnostics.

]]>
8918 DCP Archives - Clinical Value of Diagnostics nonadult
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis https://clinicalvalue.com/serum-pivka-ii-and-alpha-fetoprotein-at-virological-remission-predicts-hepatocellular-carcinoma-in-chronic-hepatitis-b-related-cirrhosis/ Mon, 19 Jun 2023 03:35:33 +0000 https://clinicalvalue.com/?p=6878 This study aimed to investigate the role of serum PIVKA-II and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission following NA therapy.

Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH...

The post Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

The risk of hepatocellular carcinoma (HCC) is reduced but not eliminated after nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB). This study aimed to investigate the role of serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission (VR) following NA therapy. 

 

Patients with CHB-related cirrhosis undergoing NA therapy from two medical centers in Taiwan were retrospectively included. Serum PIVKA-II were quantified by an automated chemiluminescence assay. Multivariable Cox proportional hazards regression models were used to identify predictors for HCC and death. Serial on-treatment PIVKA-II levels after VR were investigated.

The post Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis appeared first on Clinical Value of Diagnostics.

]]>
6878
Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis https://clinicalvalue.com/do-combined-assays-of-serum-afp-afp-l3-dcp-gp73-and-dkk-1-efficiently-improve-the-clinical-values-of-biomarkers-in-decision-making-for-hepatocellular-carcinoma-a-meta-analysis/ Mon, 19 Jun 2023 03:35:08 +0000 https://clinicalvalue.com/?p=6869 This meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.

Fang YS, Wu Q, Zhao HC, Zhou Y, Ye L, Liu SS, Li XX, Du WD...

The post Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

Serum biomarkers are valuable for clinical decision-making for patients with hepatocellular carcinoma (HCC), among which the most promising are AFP, AFP-L3, DCP, DKK-1, and GP73; however, the efficacy of using combined biomarkers remains controversial. This meta-analysis provides insights regarding this topic.

 

PubMed, Embase, and Cochrane Library were systematically surveyed, and 28 qualified articles published since January 2015 were identified. A random-effects model was used to assess pooled sensitivity, specificity, positive and negative likelihood ratios (PLRs and NLPs), and diagnostic odds ratio (DOR).

The post Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis appeared first on Clinical Value of Diagnostics.

]]>
6869
The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data https://clinicalvalue.com/the-prognostic-values-of-serum-markers-in-hepatocellular-carcinoma-after-invasive-therapies-based-on-real-world-data/ Mon, 19 Jun 2023 03:34:59 +0000 https://clinicalvalue.com/?p=6885 The purpose of this study is to evaluate the prognostic values of serum markers in HCC, with retrospective data.

Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B...

The post The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

Hepatocellular carcinoma (HCC) is one of the most common malignancies with poor prognosis, and the mortality rate remains high. More than 70% of HCC patients have recurrence within 5 years after treatment. The purpose of this study is to evaluate the prognostic values of serum markers with retrospective data.

 

Real‐world data (RWD) was applied to analyze the prognostic values of six serum markers for HCC patients after treatment, including α‐fetoprotein (AFP), α‐fetoprotein‐L3 (AFP‐L3), Golgi protein73 (GP73), alanine aminotransferase (ALT), albumin (ALB), and total bilirubin (TBil). A total of 268 cases were enrolled to analyze recurrence‐free survival (RFS), and 104 cases were used to analyze overall survival (OS).

The post The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data appeared first on Clinical Value of Diagnostics.

]]>
6885
The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients https://clinicalvalue.com/hcc-early-detection-china-pivka-ii-afp-insights/ Mon, 19 Jun 2023 03:34:08 +0000 https://clinicalvalue.com/?p=6882 This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients.

Xu F, Zhang L, He W, Song D, Ji X, Shao J...

The post The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

At present, the diagnostic accuracy of alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) surveillance is insufficient. It remains controversial whether prothrombin induced by vitamin K absence II (PIVKA-II) has a better diagnostic value than AFP for HCC patients.This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients.

 

Serum AFP and PIVKA-II levels were detected and analyzed in 308 HCC afflicted patients and 120 unafflicted controls. The receiver operator curve (ROC) and area under the curve (AUC) were conducted to evaluate the clinical value of AFP and PIVKA-II for diagnosing HCC and early HCC.

The post The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients appeared first on Clinical Value of Diagnostics.

]]>
6882
Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer https://clinicalvalue.com/efficacy-analysis-of-combined-detection-of-5-serological-tumor-markers-including-mif-and-pivka-ii-for-early-diagnosis-of-primary-hepatic-cancer/ Mon, 19 Jun 2023 03:33:39 +0000 https://clinicalvalue.com/?p=6871 The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal prothrombin (PIVKA-II) in the early diagnosis of primary liver cancer.

Huan L...

The post Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal prothrombin (PIVKA-II) in the early diagnosis of primary liver cancer.

 

A total of 90 patients with suspected primary liver cancer admitted from January 2016 to May 2017 were selected as the research subjects. All patients were examined by imaging and histopathology. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum MIF, GP73 and PIVKA-II. Automatic electrochemiluminescence immunoassay system was used to detect serum AFP and AFP-L3. The diagnostic value of single and combined detection of five serological tumor markers for primary liver cancer was compared and analyzed.

The post Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer appeared first on Clinical Value of Diagnostics.

]]>
6871
Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma https://clinicalvalue.com/clinical-utility-of-protein-induced-by-vitamin-k-absence-ii-in-patients-with-hepatocellular-carcinoma/ Wed, 19 Apr 2023 03:04:18 +0000 https://clinicalvalue.com/?p=6866 This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC.

Bhatti ABHH, Naz K, Abbas G, Khan NY, Zia HH, Ahmed IN...

The post Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

Despite moderate sensitivity, alpha fetoprotein (AFP) is widely used in screening and prognostication for hepatocellular carcinoma (HCC). The objective of the current study was to assess clinical utility of Prothrombin induced by Vitamin K absence-II (PIVKA-II) in addition to AFP in patients with HCC.

 

244 patients with documented AFP, PIVKA-II and dynamic imaging of the liver were reviewed retrospectively. Using ROC curves, cutoff values for AFP and PIVKA-II for HCC detection, tumor grade and microvascular invasion (MVI) were assessed. In patients who underwent liver transplantation (LT) for HCC, survival was determined using Kaplan Meier curves.

The post Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma appeared first on Clinical Value of Diagnostics.

]]>
6866
PIVKA-II: Confidence in HCC surveillance and diagnosis: Prof. Ming-Lung Yu https://clinicalvalue.com/pivka-ii-confidence-in-hcc-surveillance-and-diagnosis-prof-ming-lung-yu/ Wed, 12 Apr 2023 10:05:35 +0000 https://clinicalvalue.com/?p=6679 In this video, Prof Ming-Lung Yu, Chair Professor of Hepatology at Kaohsiung University Medical Hospital, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians in the early detection and overall management of HCC, and his clinical experience with PIVKA-II. ...

The post PIVKA-II: Confidence in HCC surveillance and diagnosis: Prof. Ming-Lung Yu appeared first on Clinical Value of Diagnostics.

]]>

Prof Ming-Lung Yu shares his clinical experience using PIVKA-II to complement AFP & ultrasound for early HCC detection

Find out more about PIVKA-II in Hepatocellular Carcinoma (HCC) detection, or download our HCC Detection (HD) expert pack by filling in the form below:

Get the latest updates in the liver space with our HCC detection (HD) expert pack.

Includes:

  • Highlights and a PDF copy of the latest APAC regional consensus for PIVKA-II and AFP in HCC
  • APASL 2023 Congress Report
  • Updates on future studies and patient cases

Interview transcript:

Introduction

Hello everyone, I am Dr. Ming-Lung Yu. Currently I am a physician and Chair Professor of Hepatology at the Kaohsiung Medical University Hospital and Senior Vice President of National Sun Yat-sen University.

What is the unmet need in HCC surveillance and diagnosis?

There are about 11,000 new liver cancer patients in Taiwan every year. Unfortunately, 60% of liver cancers are advanced stage at the time of first diagnosis, and usually, the effect of treatment is not satisfactory. Patients with early-stage tumors, that can be removed surgically or by ablation, have the best chance of long-term survival. Therefore, early detections of liver cancers are crucial to increase patient outcome.

What is your current HCC surveillance practice and how is PIVKA-II implemented?

Ultrasound sonography is the most important and reliable screening tool, but its sensitivity will be affected by the size and location of nodules, operation technique, fatty liver, etc. Therefore, it needs serum biomarkers as an assistant tool. AFP has been used commonly in liver cancer diagnosis now. And PIVKA-II has been used more and more in daily practice recently since it became the reimbursed item.

Why was PIVKA-II implemented in your clinical practice?

There is cumulating evidence supporting the application of PIVKA-II for HCC diagnosis. And PIVKA-II combined with AFP and ultrasound sonography can improve the sensitivity of HCC surveillance, especially in early stage of HCC.

What is your clinical experience using PIVKA-II and how effective is it in your clinical practice in HCC surveillance and diagnosis?

We observed that PIVKA-II has good sensitivity & specificity in HCC patients, and it could be better when combined with AFP & ultrasound sonography.

For BCLC stage 0/A patients, we found PIVKA-II has the best sensitivity, compared to those of ultrasound sonography and AFP.

For example, some HCC patients have no liver nodules in ultrasound sonography and with normal AFP, but have increased levels of PIVKA-II and are further confirmed by CT/MRI. Obviously, PIVKA-II is very helpful for these patient population.

How has PIVKA-II aided in your clinical decision making?

PIVKA-II can help us to have one more useful tool for improving the early diagnosis of liver cancers.

The views and opinions expressed by Prof. Ming-Lung Yu are his own views and opinions. Roche disclaims all liability in relation to these views and opinions.

The post PIVKA-II: Confidence in HCC surveillance and diagnosis: Prof. Ming-Lung Yu appeared first on Clinical Value of Diagnostics.

]]>
6679 DCP Archives - Clinical Value of Diagnostics nonadult
Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis https://clinicalvalue.com/evaluation-of-the-diagnostic-accuracy-of-des-gamma-carboxy-prothrombin-and-alpha-fetoprotein-alone-or-in-combination-for-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis/ Fri, 17 Mar 2023 07:46:55 +0000 https://clinicalvalue.com/?p=6640 This article aims to clarify the diagnostic value of DCP (PIVKA-II) and AFP in patients with different risk of HCC development (etiology, ethnicity, and various stages of tumor), and provides evidence for the two serum markers in the clinical management of patients at risk of tumor development.
Fan J, Chen Y, Zhang D, Yao J, Zhao Z, Jiang Y, Li Y, Guo Y...

The post Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis appeared first on Clinical Value of Diagnostics.

]]>

Meta-analysis to evaluate the performance & diagnostic value of AFP and PIVKA-II across different HCC risk factors

Quick Summary

This meta-analysis aimed to clarify the diagnostic value of these two serum markers in patients with different risk of HCC development, such as etiology, ethnicity, and various stages of tumor. The impact of varying study types of literature and detection methods of index test on the diagnosis outcome was also explored, providing evidence for the two serum markers in the clinical management of patients at risk of tumor development.

The authors found that overall, the diagnostic accuracy of DCP (PIVKA-II) was superior to AFP. However, the diagnostic performance of AFP and DCP (PIVKA-II) was different in different ethnicity, etiology, and detection methods. The authors concluded that the combination of DCP (PIVKA-II) and AFP can improve the effectiveness of surveillance for patients at risk of HCC.

The post Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis appeared first on Clinical Value of Diagnostics.

]]>
6640
A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma https://clinicalvalue.com/a-meta-analysis-and-of-clinical-values-of-11-blood-biomarkers-such-as-afp-dcp-and-gp73-for-diagnosis-of-hepatocellular-carcinoma/ Fri, 17 Mar 2023 07:44:43 +0000 https://clinicalvalue.com/?p=6634 This study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically.
Pang BY, Leng Y, Wang X, Wang YQ, Jiang LH...

The post A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma appeared first on Clinical Value of Diagnostics.

]]>

Meta-analysis of biomarkers for HCC diagnosis, including AFP, DCP (PIVKA-II), GPC3, GP73, Hsp90alpha, midkine, and OPN

Quick Summary

Hepatocellular carcinoma lacks ideal diagnostic biomarkers. There is a lack of scientific evaluation of relevant promising biomarkers as well. Therefore this study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically.

The authors found that the combination of AFP and other biomarkers improved the diagnostic efficiency. The diagnostic value of biomarkers including DCP (PIVKA-II), GPC3, GP73, Hsp90alpha, midkine, and OPN was higher than that of AFP. GP73 had the best diagnostic value for HCC.

The post A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma appeared first on Clinical Value of Diagnostics.

]]>
6634